Related Experiment Video
Updated: Jul 2, 2025
05:14
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
1.1K
Morphological Biomarkers Related to Visual Acuity in Patients With Radiation Retinopathy Treated With Intravitreal
Ophthalmic Surgery, Lasers & Imaging Retina
|February 26, 2024
Summary
Spectral-domain optical coherence tomography (SD-OCT) identified intraretinal cyst size and neovascularization as key biomarkers for predicting vision loss in radiation retinopathy (RR). These findings help characterize the course of visual decline in RR patients.
Area of Science:
- Ophthalmology
- Medical Imaging
- Retinal Diseases
Background:
- Radiation retinopathy (RR) is a vision-threatening complication.
- Identifying biomarkers for visual acuity (BCVA) is crucial for managing RR.
- Spectral-domain optical coherence tomography (SD-OCT) offers detailed retinal imaging.
Purpose of the Study:
- To monitor variables using SD-OCT.
- To identify biomarkers related to BCVA in RR.
- To analyze the prognostic value of OCT parameters in RR.
Main Methods:
- Post-hoc analysis of the Ranibizumab for Radiation Retinopathy (RRR) trial.
- Evaluation of SD-OCT parameters including intraretinal fluid, ellipsoid zone (EZ) disruption, and neovascularization.
- Univariate analysis and mixed-effects modeling to assess the relationship between OCT parameters and BCVA.
Main Results:
- Intraretinal cyst vertical size and neovascularization were significantly associated with BCVA at multiple time points.
- Ellipsoid zone (EZ) disruption was relevant in univariate analysis but not confirmed in the mixed-effects model.
- The mixed-effects model confirmed intraretinal cyst vertical size and neovascularization as significant predictors of BCVA.
Conclusions:
- Intraretinal cyst vertical size and neovascularization are key biomarkers for predicting poor BCVA in RR.
- These findings help characterize the natural course of visual loss in RR.
- Larger multicenter studies are recommended to validate these biomarkers.
